Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Text Size

A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma

This study has been completed.
Sponsor:
Collaborator:
Millennium Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Seattle Genetics, Inc.
ClinicalTrials.gov Identifier:
NCT00866047
First received: March 19, 2009
Last updated: August 12, 2016
Last verified: August 2016
History of Changes
Results First Received: September 15, 2011  
Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Conditions: Lymphoma, Large-Cell, Anaplastic
Lymphoma, Non-Hodgkin
Intervention: Drug: brentuximab vedotin

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Enrollment period: Jun 2009 - May 2010

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Brentuximab Vedotin Brentuximab vedotin 1.8 mg/kg every 3 weeks by intravenous (IV) infusion

Participant Flow for 2 periods

 Period 1:   Treatment Period
    Brentuximab Vedotin  
STARTED     58  
COMPLETED     3 [1]
NOT COMPLETED     55  
Progressive disease                 13  
Adverse Event                 14  
Physician Decision                 14  
Withdrawal by Subject                 5  
Continuing on treatment                 9  
[1] Number who completed 16 cycles of treatment

Period 2:   Follow-up Period
    Brentuximab Vedotin  
STARTED     43 [1]
COMPLETED     12 [2]
NOT COMPLETED     31  
Continuing in follow-up                 31  
[1] All participants were to be followed after treatment
[2] Completed survival follow-up due to death



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Brentuximab Vedotin Brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion

Baseline Measures
    Brentuximab Vedotin  
Number of Participants  
[units: participants]
 		  58  
Age, Customized  
[units: years]
Median (Full Range) 		  52.0  
  (14 to 76)  
Gender  
[units: participants]
 		 
Female     25  
Male     33  
Race (NIH/OMB)  
[units: participants]
 		 
American Indian or Alaska Native     0  
Asian     1  
Native Hawaiian or Other Pacific Islander     0  
Black or African American     7  
White     48  
More than one race     0  
Unknown or Not Reported     2  
Eastern Cooperative Oncology Group Performance Status [1]
[units: participants]
 		 
0     19  
1     38  
2     1  
3-5     0  
ALK Status [2]
[units: participants]
 		 
Positive     16  
Negative     42  
[1]

0 = Normal activity

  1. = Symptoms but ambulatory
  2. = In bed <50% of the time
  3. = In bed >50% of the time
  4. = 100% bedridden
  5. = Dead
[2] Immunophenotype status with respect to anaplastic lymphoma kinase (ALK) protein



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Objective Response Rate by Independent Review Group   [ Time Frame: up to 12 months ]
  Show Outcome Measure 1

2.  Secondary:   Complete Remission Rate by Independent Review Group   [ Time Frame: up to 12 months ]
  Show Outcome Measure 2

3.  Secondary:   Duration of Objective Response by Kaplan-Meier Analysis   [ Time Frame: up to 17.5 months ]
  Show Outcome Measure 3

4.  Secondary:   Duration of Objective Response in Participants With Complete Remission by Kaplan-Meier Analysis   [ Time Frame: up to 17.5 months ]
  Show Outcome Measure 4

5.  Secondary:   Progression-free Survival by Kaplan-Meier Analysis   [ Time Frame: up to 17.5 months ]
  Show Outcome Measure 5

6.  Secondary:   Overall Survival   [ Time Frame: up to 17.5 months ]
  Show Outcome Measure 6

7.  Secondary:   Adverse Events by Severity, Seriousness, and Relationship to Treatment   [ Time Frame: up to 12 months ]
  Show Outcome Measure 7

8.  Secondary:   Hematology Laboratory Abnormalities >/= Grade 3   [ Time Frame: up to 12 months ]
  Show Outcome Measure 8

9.  Secondary:   Chemistry Laboratory Abnormalities >/= Grade 3   [ Time Frame: up to 12 months ]
  Show Outcome Measure 9

10.  Secondary:   Area Under the Curve   [ Time Frame: 3 weeks ]
  Show Outcome Measure 10

11.  Secondary:   Maximum Serum Concentration   [ Time Frame: 3 weeks ]
  Show Outcome Measure 11

12.  Secondary:   Time of Maximum Serum Concentration   [ Time Frame: 3 weeks ]
  Show Outcome Measure 12

13.  Other Pre-specified:   B Symptom Resolution   [ Time Frame: up to 12 months ]
  Show Outcome Measure 13


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  Limitations and Caveats
  Show Limitations and Caveats


  More Information
  Show More Information